Immune targeted therapy for diffuse large B cell lymphoma. Issue 4 (October 2021)

• Record Type: Journal Article
• Authors: Zheng, Yaxin; Si, Junqi; Yuan, Tian; Ding, Sa; Tian, Chen
• Is Part Of: Blood science. Volume 3:Issue 4(2021)
• Page Start: 136
• Page End: 148
• Publication Date: 2021-10
• Subjects: Antibody-drug conjugates -- Checkpoint inhibitors -- DLBCL -- Monoclonal antibodies -- Signaling pathway inhibitors; Hematology -- Periodicals; Blood -- Periodicals; Hematology; Blood; Hematology; Blood; Electronic journals; Periodicals; 616.15005
• DOI: 10.1097/BS9.0000000000000095
• Languages: English
• ISSNs: 2543-6368

Abstract

Abstract : Abstract: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.